(Boursier.com) — Late-breaking data from the NOTUS phase III study evaluating the experimental use of Dupixent (dupilumab) in the adjunctive maintenance treatment of uncontrolled COPD in adults on maximum inhaled treatment of reference (triple therapy in almost all cases) with type 2 inflammation were presented in a topical session at the 2024 International Congress of the American Thoracic Society (ATS) and published simultaneously in the New England Journal of Medicine (NEJM).
These data confirm the decisive positive results obtained in the phase III BOREAS study.
Dr. Surya Bhatt, MSPH, Associate Professor, University of Alabama at Birmingham, Division of Respiratory Allergy and Emergency Medicine, and co-principal investigator of the study said, “I have been practicing medicine for over 20 years and, throughout these years, very little therapeutic progress has been made for patients struggling with the disabling effects of uncontrolled COPD. Too many of them are also victims of cycles of. very distressing exacerbations that could lead to significant deterioration in their respiratory function and quality of life. In the NOTUS study, dupilumab reduced COPD exacerbations to a magnitude never before observed in a clinical study. phase III study for an investigational biological drug. These comprehensive results clearly show that, if approved, dupilumab could become the first drug in its class to advance the treatment of patients with COPD.”
As demonstrated by the presented and published data, the NOTUS study met its primary and key secondary endpoints.
All patients were on maximum reference inhaled treatment (on triple therapy for almost the majority of them).
©2024 Boursier.com